Company

Bank

Analyst

Coverage

Opinion

Wk chg

2/17 cls

BG Medicine Inc. (NASDAQ:BGMD)

Ladenburg Thalmann

Kevin DeGeeter

Price target

Buy

-7%

$7.90

DeGeeter raised his target to $16.50 from $8.25 after BG Medicine reported data from the pivotal BioImage Study. The data showed that testing with its CardioScore diagnostic at baseline significantly improved the identification of subjects at high risk for near-term major cardiovascular events over conventional risk scoring throughout a median follow-up of 2.5 years. DeGeeter estimates peak gross sales of $325M for CardioScore, which is an in vitro diagnostic multivariate index (IVDMIA) assay that measures seven protein biomarkers in blood. Last December, BG Medicine submitted a 510(k) application to FDA for the test to identify patients at high risk for near-term major cardiovascular events, including myocardial infarction and stroke.

Medivation Inc. (NASDAQ:MDVN)

William Blair

Y. Katherine Xu

Price target

Outperform

-3%

$66.05